The “Global Biosimilars market, By Recombinant Products (Non-Glycosylated Proteins, Glycosylated Proteins, peptides and others) By Application (Oncology, Blood Disorders, Chronic and Auto-immune Disease, infectious diseases and others) opportunities and forecast 2017-2025″ report has been added to Reports Monitor’s database.
Biosimilars are the copied version of biologics that have undergone patent expiration. The major factors that are driving the growth of the market includes increasing demand for these drugs due to rising geriatric population, their cost-effectiveness, strategic collaborations ensuring enhanced throughput and clinical trial activities for these drugs, and increasing support from the government and initiatives to develop and promote these drugs.
Europe has around 27 biosimilars drugs available, US has been slower to hold on this trend. Recently, the growth is accelerating due to patent expiration of popular biologics. Also, it is expected that the rising acceptance of these drugs by governments and physicians, and the growth of real-world evidence will help build patient confidence and trust with regards to the efficacy and safety of these products. This, in turn will drive growth in the market. Furthermore, as the price of these drugs is 30 to 50 per cent lower than the originals, there exist huge potential healthcare cost savings, which will also drive the market for these copied drugs. Currently, there are more of these drugs in progress across the Asia-Pacific than anywhere else, leading to numerous great opportunities. Producers of these drugs in Asian countries share various benefits over their competitors in US and EU markets.
Over the next three to four years, it will be significantly easier to obtain sanction for these drugs development in the U.S. The faster drug makers can get these drugs through the governing agencies, and as the cost of developing these drugs decreases, the greater the chances will be for more firms to step in and create impact on the industry. With more players producing these drugs, there will be more options which mean a bigger number of people will be able to obtain the benefits, these drugs provide. Also, it is expected that the market won’t be able to withstand the large number of participants in the long term, hence it is expected that only the most successful businesses sustaining a presence. Companies like Teva and Coherus, Sandoz are anticipated to show a great deal of progress over the next decade as they bring more of these products to market. This is the market that will continue to be in focus in this billion-dollar business industry with the probability of changing the industry forever.
To be successful in the sector, companies must implement the quality and latest technology initiatives, such as design of experiments, quality by design, and process analytical technology. They also take a practical approach in risk mitigation by accumulating risk management plans and accepting production best practices that are outlined by regulatory agencies and industry associations.
The 2017 version of the Global Biosimilars market report provides important statistics related to the overall market and price forecast over a five-year period, from 2017 to 2025. In this segment, the experts have offered essential information which relates to the production and consumption forecast for the major regions that the market is categorized into, production forecast by type, and consumption forecast by application.
Along with the distributors/traders, the report gives a nearby perspective of some essential viewpoints, for example, marketing channel and market situating. Under marketing channel, the analysts have given a clear comprehension of direct and indirect marketing and significant marketing channel development trends. In like manner, the market situating area involves some essential points, viz. Estimating procedure, mark technique, and target customer.
The segmentation illustrated in the report introduces the Biosimilars market while taking into account three key parameters. By application and product type, the market is divided into three segments each, whereas on the basis of geography, the report studies North America, Europe, Asia Pacific, LAMEA as the leading regions. Considering the different types of Biosimilars, the report evaluates the market by market share, revenue, price, and production growth throughout the same period. By region, the analysts have examined the market with regard to the supply, import, export, and consumption factors.
The manufacturing cost analysis depicted in the immeasurable, yet exact distribution has offered a solid examination of the key raw materials in the Biosimilars Market, other than their suppliers, market concentration rate, and price trends. Purchasers of the report additionally have admittance to the manufacturing process analysis and cost structure, including raw materials, labor cost, and manufacturing expenses.
The report is a fine asset to track the wellsprings of raw materials utilized by the significant makers in the market, upstream raw materials sourcing, and downstream purchasers. With the steadfast research discoveries and conclusion exhibited in the report, report purchasers can acquire help with settling on educated business choices and take the prescribed way for business development in the Biosimilars market.
According to the report, some of the crucial competitors prevailing in the Biosimilars market are Pfizer Inc., Teva Pharmaceuticals, Sandoz International GmBH, Biocon Ltd, F. Hoffmann-La Roche Ltd., Celltrion Inc., Amgen, STADA, Merck and Co., Biogen.
Each of these players is studied in the report using selective company profiling, which decodes their production, revenue, price, and gross margin and evaluates them based on salient determinants such as product type, application, specification, manufacturing base, and rivalries.